656257-69-1

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 66572-56-3 2-bromoisonicotinic acid 
• 16645-06-0 N,N-dimethylhydroxylamine hydrochloride 

Downstream Products

• 111043-06-2 1-(2-bromo-4-pyridinyl)ethanone 
• 1187669-38-0 4-(2-bromo-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-43-7 4-(2-ethyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-71-1 N,N-dimethyl-4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-pyridin-2-amine 
• 1187669-42-6 4-(2-ethynyl-4-pyridinyl)-N-(3-methylphenyl)-1,3-thiazol-2-amine 
• 1187669-45-9 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-2-pyridinyl)-1-propanol 
• 1187669-44-8 3-(4-{2-[(3-methylphenyl)amino]-1,3-thiazol-4-yl}-2-pyridinyl)-2-propyn-1-ol 
• 1187669-69-7 N-(3-methylphenyl)-4-[2-morpholin-4-yl-pyridin-4-yl]-1,3-thiazol-2-amine 
• 1187669-70-0 N-(3-methylphenyl)-4-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1,3-thiazol-2-amine 
• 1366407-37-5 1-[2-(4-fluorophenyl)pyridin-4-yl]ethanone 
• 1595292-44-6 2-[(diphenylmethylene)amino]-N-methoxy-N-methylisonicotinamide 

Relevant academic research and scientific papers

Aminopyridyloxypyrazole derivative and preparation method and application thereof

The invention relates to an aminopyridyloxypyrazole derivative and a preparation method and application thereof. The structure of the aminopyridyloxypyrazole derivative is shown as a formula (I). The invention provides a brand-new aminopyridyloxypyrazole derivative which has obvious effects of inhibiting TGF [beta] R1 (ALK5) kinase activity and treating cancer or fibrosis related diseases, and the preparation method of the derivative is simple and easy to operate.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

FARNESOID X RECEPTOR AGONISTS AND USES THEREOF

Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.

MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.

IRAK4 INHIBITING AGENTS

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

BTK INHIBITORS

The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I) or pharmaceutically acceptable salts thereof. (Formula I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.

Pyrrolydine Derivatives as IAP Inhibitors

The present invention relates to novel IAP inhibitor compounds of: Formula (I).